Current biological and pharmacological updates on wogonin

Simple item page
dc.contributor.authorRawat, Sarita
dc.contributor.authorGupta, Gaurav
dc.contributor.authorPathak, Sachchidanand
dc.contributor.authorSingh, Santosh Kumar
dc.contributor.authorSingh, Himmat
dc.contributor.authorMishra, Anurag
dc.contributor.authorGilhotra, Ritu
dc.contributor.authorAljabali, Alaa A. A.
dc.contributor.authorDureja, Harish
dc.contributor.authorTambuwala, Murtaza M.
dc.contributor.authorChellappan, Dinesh K.
dc.contributor.authorDua, Kamal
dc.date.accessioned2020-12-18T13:11:23Z
dc.date.available2020-12-18T13:11:23Z
dc.date.issued2020-05-13
dc.description.abstractWogonin (5, 7-Dihydroxy-8-methoxyflavone) is a traditional naturally occurring flavonoid derived from the root extract of Chinese medicine, named Scutellaria baicalensis Georgi. Wogonin contains various biological properties which include allergic diseases, anti-cancertherapy and anti-inflammatory activities. Wogonin also shows the effects of removing toxins and cleansing heat. Wogonin glycosides are known as wogonosides. Oroxindin, a wogonin glucuronide isolated from Oroxylum indicum, is one of the example of wogonoside. It is also used in Japanese herbal supplement named Sho-Saiko-To, as an important active ingredient. One of the major active constituents of wogonin, Scutellaria baicalensis, shows potent anticancer activities both in vivo and in vitro studies. The anticancer therapeutic activity of wogonin has been shown by regulation of different cell signaling pathways , which includes protein kinase B pathway (serine-threonine kinase) and AMP-activated protein kinase pathways. Wogonin also shows positive therapeutic anticancer effects in breast cancer by inhibiting the 5‑LO/BLT2/ERK/IL‑8/MMP‑9 signaling cascade and established a major pharmacological anticancer activity.en
dc.identifier.citationRawat, S., Gupta, G., Pathak, S., Singh, S. K., Singh, H., Mishra, A., Gilhotra, R., Aljabali, A. A. A., Dureja, H., Tambuwala, M. M., Chellappan, D. K., & Dua, K. (2020). Current biological and pharmacological updates on wogonin. EXCLI Journal, 19, 635-640. https://doi.org/10.17179/excli2020-1967en
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/39957
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-21847
dc.language.isoen
dc.publisherIfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmunden
dc.relation.ispartofseriesEXCLI Journal;Vol. 19 2020
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectWogoninen
dc.subjectAnticanceren
dc.subjectAntiinflammatoryen
dc.subjectHepatoprotectiveen
dc.subject.ddc610
dc.titleCurrent biological and pharmacological updates on wogoninen
dc.typeText
dc.type.publicationtypearticle
dcterms.accessRightsopen access
eldorado.dnb.zdberstkatid2132560-1
eldorado.identifier.urlhttps://www.excli.de/index.php/excli/article/view/1967
eldorado.secondarypublicationtrue

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
excli2020-1967.pdf
Size:
202.81 KB
Format:
Adobe Portable Document Format
Description:
DNB
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Letters to the Editor 2020